Dr. Christopher S. King, MD
Critical Care Medicine (Critical Care Medicine (Internal Medicine) Physician)
- Medicare participating
At a glance
- Medical school
- University of Maryland School of Medicine (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 370
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: University of Maryland School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Critical Care Medicine (Internal Medicine) Physician primary
VA license 0101236702 -
Internal Medicine Physician
VA license 0101236702 -
Pulmonary Disease Physician
VA license 0101236702
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Inova Fairfax Hospital Falls Church, VA
- Inova Alexandria Hospital Alexandria, VA
- Inova Loudoun Hospital Leesburg, VA
- Holy Cross Hospital Silver Spring, MD
Medical groups
- Inova Health Care Services (1,817 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 370
- Services billed
- 922
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 217 | 71 |
| Test for exercise-induced lung stress | 141 | 128 |
| Established patient office or other outpatient visit, 40-54 minutes | 136 | 79 |
| Test to measure expiratory airflow and volume | 101 | 95 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 47 | 39 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 27 | 25 |
| Critical care, first 30-74 minutes | 26 | 13 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 24 | 20 |
| New patient office or other outpatient visit, 60-74 minutes | 18 | 18 |
| Established patient office or other outpatient visit, 30-39 minutes | 18 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ofev (nintedanib esylate) | 117 |
| Prednisone Other prescribers in Falls Church, VA | 94 |
| Sildenafil Citrate Other prescribers in Falls Church, VA | 83 |
| Furosemide Other prescribers in Falls Church, VA | 67 |
| Adempas (riociguat) | 46 |
| Mycophenolate Mofetil Other prescribers in Falls Church, VA | 40 |
| Orenitram Er (treprostinil diolamine) | 38 |
| Pirfenidone | 37 |
| Spironolactone Other prescribers in Falls Church, VA | 35 |
| Tadalafil | 35 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 29 payments worth $9,912 in total to this clinician.
| Merck Sharp & Dohme LLC | $6,474 |
|---|---|
| United Therapeutics Corporation | $3,214 |
| Actelion Pharmaceuticals US, Inc. | $88.90 |
| Insmed, Inc. | $41.86 |
| Astellas Pharma US Inc | $32.22 |
| AbbVie Inc. | $25.57 |
| Johnson & Johnson Health Care Systems Inc. | $20.93 |
| Invivyd Inc | $14.69 |
| Consulting Fee | $5,760 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $2,540 |
| Food and Beverage | $1,118 |
| Travel and Lodging | $494 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Jul 1, 2025 | Consulting Fee | $5,760 |
| United Therapeutics Corporation May 20, 2025 | Compensation for services other than consulting (speaking, faculty) TYVASO · Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lun | $1,270 |
| United Therapeutics Corporation Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) TYVASO · Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lun | $1,270 |
| Merck Sharp & Dohme LLC Jun 19, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Philadelphia, PA · in-kind | $272 |
| Merck Sharp & Dohme LLC Jul 1, 2025 | Travel and Lodging travel to Philadelphia, PA | $150 |
| Merck Sharp & Dohme LLC Jun 19, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Philadelphia, PA | $72.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $446,150 in research payments for these studies, mostly to the institutions running them.
- Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
United Therapeutics Corporation · Completed · NCT04708782 - Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
United Therapeutics Corporation · Enrolling by invitation · NCT04905693 - Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
United Therapeutics Corporation · Recruiting · NCT05943535 - Randomized, Double-Blinded, Placebo-Controlled Phase 2 Study for the Long-Term Evaluation of Fostamatinib for the Treatment of Adult Patients with Acute Respiratory Distress Syndrome (ARDS)
Rigel Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.